CytomX Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-17.4M | $31.9M | $-569.0K | $-99.3M | $-115.9M | $-64.8M | $-132.8M | $-84.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | $1.9M |
| Depreciation | $1.2M | $1.6M | $2.0M | $2.3M | $2.6M | $2.4M | $2.5M | $1.7M |
| Amortization | $146.0K | $146.0K | $146.0K | $146.0K | $146.0K | $146.0K | $146.0K | $146.0K |
| Stock-Based Compensation | $6.3M | $7.7M | $8.6M | $13.1M | $13.2M | $14.8M | $19.1M | $16.9M |
| Net Cash from Operating Activities | $-75.6M | $-86.2M | $-56.0M | $-110.8M | $-119.0M | $5.3M | $-140.5M | $-75.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $220.0K | $310.0K | $840.0K | $1.7M | $1.6M | $2.3M | $3.5M | $3.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-59.7M | $99.7M | $-150.7M | $98.3M | $22.5M | $-18.7M | $79.7M | $5.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $110.4M | $7.5M | $30.2M | $648.0K | $110.2M | $16.9M | $1.6M | $139.6M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-75.8M | $-86.5M | $-56.9M | $-112.5M | $-120.6M | $3.0M | $-144.0M | $-79.3M |